| 201 |
18281755 | [Prediction of response to docetaxel in breast cancer]. | 2008 Feb |
1 |
| 202 |
18448549 | Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. | 2008 Apr |
2 |
| 203 |
18766004 | Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. | 2008 Oct |
1 |
| 204 |
18799033 | [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer]. | 2008 Sep |
3 |
| 205 |
19068453 | A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer. | 2008 Dec |
1 |
| 206 |
19169606 | [Optimal role of docetaxel in adjuvant chemotherapy for early stage HER2-negative breast cancer]. | 2008 Nov-Dec |
2 |
| 207 |
19169607 | Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. | 2008 Nov-Dec |
1 |
| 208 |
21479380 | Relationship between the signal ratios of HER-2/CEP17 and c-MYC/CEP17 and the pathological response of neoadjuvant therapy using docetaxel and trastuzumab in breast cancer. | 2008 Jan-Feb |
1 |
| 209 |
17010609 | Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. | 2007 Feb |
1 |
| 210 |
17211467 | Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. | 2007 Jan 29 |
5 |
| 211 |
17296975 | Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. | 2007 Apr 1 |
3 |
| 212 |
17324279 | HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. | 2007 Feb 26 |
2 |
| 213 |
17370037 | Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. | 2007 Oct |
2 |
| 214 |
17449250 | The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. | 2007 Jun |
1 |
| 215 |
17515572 | Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. | 2007 Jul 1 |
1 |
| 216 |
17592672 | Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. | 2007 Jun |
1 |
| 217 |
18034988 | Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer. | 2007 Nov-Dec |
2 |
| 218 |
19804028 | Docetaxel plus trastuzumab as treatment for HER-2 positive metastatic breast cancer: review of the existing evidence. | 2007 Sep |
2 |
| 219 |
16332965 | Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. | 2006 Mar |
2 |
| 220 |
16495393 | Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. | 2006 Feb 23 |
1 |
| 221 |
16549824 | Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. | 2006 Apr 20 |
3 |
| 222 |
16755112 | Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. | 2006 |
3 |
| 223 |
16805818 | Predictive factors for response to docetaxel in human breast cancers. | 2006 Sep |
1 |
| 224 |
16912526 | [Biweekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients]. | 2006 Aug |
2 |
| 225 |
17033229 | [Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial]. | 2006 Oct |
1 |
| 226 |
15748465 | Weekly docetaxel/carboplatin as primary systemic therapy for HER2-negative locally advanced breast cancer. | 2005 Feb |
1 |
| 227 |
15791816 | [Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients]. | 2005 Mar |
3 |
| 228 |
15834928 | HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. | 2005 Jun 1 |
9 |
| 229 |
15911866 | Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. | 2005 Jul 1 |
1 |
| 230 |
16199990 | Hypofractionated accelerated radiotherapy with cytoprotection combined with trastuzumab, liposomal doxorubicine, and docetaxel in c-erbB-2-positive breast cancer. | 2005 Oct |
1 |
| 231 |
16315942 | [Combination immunotherapy using autologous tumor-stimulated lymphocytes and trastuzumab (Herceptin) for the patients with recurrent breast cancer]. | 2005 Oct |
1 |
| 232 |
14967075 | Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial. | 2004 Jan |
1 |
| 233 |
14999148 | Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). | 2004 Mar |
14 |
| 234 |
15017597 | A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. | 2004 Mar |
1 |
| 235 |
15020608 | Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. | 2004 Mar 15 |
3 |
| 236 |
15023243 | Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. | 2004 Feb |
2 |
| 237 |
15031597 | A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. | 2004 |
1 |
| 238 |
15074734 | Trastuzumab and docetaxel for metastatic breast cancer: an experience from a cancer centre in India. | 2004 Apr |
2 |
| 239 |
15138562 | Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. | 2004 Jun |
1 |
| 240 |
15139054 | Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. | 2004 May 15 |
2 |
| 241 |
15150304 | Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. | 2004 May 19 |
3 |
| 242 |
15311558 | Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. | 2004 Jun |
1 |
| 243 |
15325672 | Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation. | 2004 Aug |
1 |
| 244 |
15366720 | [Adjuvant chemotherapy with taxoid-containing drugs in breast cancer: soon to be expected in the Netherlands]. | 2004 Jul 31 |
1 |
| 245 |
15567936 | HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. | 2004 Aug |
2 |
| 246 |
15585076 | Docetaxel and cisplatin as primary chemotherapy for treatment of locally advanced breast cancers. | 2004 Dec |
1 |
| 247 |
12576925 | Decreased response to paclitaxel versus docetaxel in HER-2/neu transfected human breast cancer cells. | 2003 Feb |
4 |
| 248 |
12576933 | Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer: a pilot phase II study. | 2003 Feb |
2 |
| 249 |
12820439 | The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? | 2003 Mar-Apr |
3 |
| 250 |
12902864 | Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. | 2003 Aug |
1 |